What is Encorafenib and what does it treat
Encorafenib is an oral BRAF kinase inhibitor used to treat malignant tumors carrying BRAF V600E/K mutations, including melanoma, colorectal cancer, and non-small cell lung cancer, in combination with specific targeted drugs.
1. Basic information of the drug
(1) Common names: Enkofeni, Konafenib
(2) Product Name: Braftovi
(3) Dosage form: 75mg hard capsule, beige cap printed with "A", white body printed with "LGX75mg".
2. Scope of treatment for diseases
(1) Melanoma: Combination therapy with bimetinib for BRAF V600E/K mutation unresectable or metastatic melanoma
(2) Colorectal cancer: Combination therapy with cetuximab for BRAF V600E mutant metastatic colorectal cancer
(3) Non small cell lung cancer: combined treatment with bimetinib for BRAF V600E mutant metastatic NSCLC.
3 mechanisms of action
(1) Target: Selective inhibition of BRAF V600E/K mutant protein
(2) Principle: Block the MAPK signaling pathway, inhibit tumor cell proliferation, and induce apoptosis.
4 Medication precautions
(1) Genetic testing is required to confirm the mutation status
(2) The combination therapy regimen must strictly follow the guidelines
(3) Common side effects include skin reactions, liver toxicity, and QT interval prolongation.
5 Market Status
(1) Not listed domestically, no generic drugs
(2) Need to obtain through overseas channels, pay attention to the authenticity of drugs.
Disclaimer：《What is Encorafenib and what does it treat》Edited and sorted by Seagull Pharmacy's editors. Please contact us in time if there is any infringement. In addition, the suggestions for drug usage, dosage and disease mentioned in the article are only for medical staff's reference, and can not be used as any basis for medication！